Cure My Disease

Don't miss your cure!

 Log in / Sign up

MS drug trial halted after failing to lower nerve damage

NCT ID NCT05630547

Terminated Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an oral drug called SAR443820 in 174 adults with multiple sclerosis (MS) to see if it could lower a marker of nerve damage in the blood. The trial was stopped early because the drug did not meet its main goal of reducing that marker. Participants were followed for up to 96 weeks, but the study ended before completion.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple sclerosis primary progressive multiple sclerosis relapsing-remitting multiple sclerosis secondary progressive multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SCLEROSIS

Contacts and locations

Locations

  • Investigational Site Number : 0560001

    Brussels, BE-1200, Belgium

  • Investigational Site Number : 0560002

    Ghent, 9000, Belgium

  • Investigational Site Number : 0560003

    Overpelt, 3900, Belgium

  • Investigational Site Number : 1000001

    Sofia, 1407, Bulgaria

  • Investigational Site Number : 1000002

    Sofia, 1431, Bulgaria

  • Investigational Site Number : 1000003

    Sofia, 1680, Bulgaria

  • Investigational Site Number : 1240001

    Gatineau, Quebec, J8Y 1W2, Canada

  • Investigational Site Number : 1240002

    Ottawa, Ontario, K1H 8L6, Canada

  • Investigational Site Number : 1240003

    Lévis, Quebec, G6W0M5, Canada

  • Investigational Site Number : 1240004

    Toronto, Ontario, M5B 1W8, Canada

  • Investigational Site Number : 1520001

    Santiago, Reg Metropolitana de Santiago, 8380456, Chile

  • Investigational Site Number : 1560001

    Tianjin, 300052, China

  • Investigational Site Number : 1560002

    Shanghai, 200040, China

  • Investigational Site Number : 1560003

    Chengdu, 610041, China

  • Investigational Site Number : 1560004

    Xi'an, 710038, China

  • Investigational Site Number : 2500001

    Paris, 75013, France

  • Investigational Site Number : 2500002

    Nice, 06001, France

  • Investigational Site Number : 2500003

    Strasbourg, 67098, France

  • Investigational Site Number : 2500004

    Caen, 14033, France

  • Investigational Site Number : 2760002

    Würzburg, 97074, Germany

  • Investigational Site Number : 3800001

    Pozzilli, Isernia, 86077, Italy

  • Investigational Site Number : 3800002

    Milan, 20132, Italy

  • Investigational Site Number : 3800003

    Milan, 20133, Italy

  • Investigational Site Number : 3800005

    Cagliari, 09126, Italy

  • Investigational Site Number : 6160001

    Krakow, 31-503, Poland

  • Investigational Site Number : 6160002

    Katowice, Silesian Voivodeship, 40-571, Poland

  • Investigational Site Number : 6160004

    Plewiska, Greater Poland Voivodeship, 62-064, Poland

  • Investigational Site Number : 6160005

    Katowice, Silesian Voivodeship, 40-686, Poland

  • Investigational Site Number : 6160006

    Zabrze, 41-800, Poland

  • Investigational Site Number : 7240001

    Barcelona, Barcelona [Barcelona], 08035, Spain

  • Investigational Site Number : 7240002

    Seville, Andalusia, 41009, Spain

  • Investigational Site Number : 7240003

    Madrid, Madrid, Comunidad de, 28040, Spain

  • Investigational Site Number : 7240004

    Madrid / Madrid, Madrid, Comunidad de, 28007, Spain

  • Investigational Site Number : 7240005

    Murcia, 30120, Spain

  • Investigational Site Number : 7240006

    Madrid, 28034, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.